Cardiac Remote Monitoring Platform

Alerts Customized Your Way

by Robin Leahy, MSPH, BSN, RN, PaceMate Vice President of Compliance

PaceMate brings impressive advantages to CIED (Cardiac Implantable Electronic Devices) remote monitoring programs. Our unique, proprietary alerts engine is particularly beneficial, a true differentiator from other RM platforms.

PaceMateLIVE Prioritizes Clinically Actionable Alerts
In an environment where CIED implant volumes continue to grow, the subsequent volume of remote monitoring alerts creates a huge burden on already overextended clinical teams. PaceMate’s technology-enabled alert mitigation is a sustainable method to discern clinically actionable alerts from non-clinically actionable alerts. This helps to direct stretched resources toward clinically relevant data that needs to be prioritized.

This level of alert management and customization is possible because of PaceMate’s revolutionary EHR (electronic health record) integrations with marketplace EHR vendors such as Epic, Cerner and athenahealth, as well as PaceMate’s automation capabilities.

  • PaceMate alerts are customized by the physician and are configurable at the patient, physician, practice, or diagnosis level.
  • PaceMate’s robust FHIR (fast healthcare interoperability resources) API (application programming interfaces) integrations allow PaceMateLIVE to adjudicate device-level alerts based on medication and diagnosis data that is automatically updated on every report from the EHR.

PaceMate customers with these integrations do not rely on stagnant data. Rather, the most up-to-date EHR data, the source of truth, helps to fuel our proprietary alerts engine—saving providers time and promoting quality by allowing clinicians to prioritize the most clinically relevant patient and device findings. For providers who want to be alerted to atrial fibrillation events only in the absence of anticoagulation or rate control, PaceMateLIVE is a gamechanger.

PaceMate Data-Driven Research
The capabilities of the PaceMateLIVE alerts engine, coupled with our platform’s vast, queryable CIED data repository, enables researchers to answer valuable scientific questions related to the management of patients with CIEDs.

Most recently, utilization of PaceMate’s clinical services, software, and data enabled O’Shea, et al. to examine anticoagulation practices related to device-detected atrial fibrillation.

  • The study population was intensively managed with PaceMate’s software + service solution.
  • Atrial fibrillation (AF) events were identified in patients with a dual chamber pacemaker, implantable cardioverter defibrillator (ICD), CRT-D, CRT-P, or implantable loop recorder (ILR).
  • AF events were classified by total duration and stroke risk, using patient age and heart failure diagnosis data.
  • Investigators were able to identify anticoagulation status through PaceMateLIVE.
  • While early detection of AF with significant duration was captured with intensive remote monitoring, anticoagulation rates were lower than expected, particularly in the older study population.
  • Recommendations from the authors focus on the development of remote monitoring care pathways to address device detection episodes of atrial fibrillation.

PaceMate’s ability to leverage patient demographic, medication, diagnosis, and hospitalization data with device data and device-detected patient data, supports not only efficient and efficacious patient care, but also quality improvement activities at the population and practice levels, as well as large-scale research studies.

Talk with our team today to find out how your device clinic or healthcare system can leverage PaceMate technology to realize greater operational efficiency.

O’Shea CJ, Brooks AG, Middeldorp ME, et al. Device-detected atrial fibrillation in a large remote-monitored cohort: Implications for anticoagulation and need for new pathways of service delivery. Journal of Interventional Cardiac Electrophysiology. https://doi.org/10.1007/s10840-023-01481-4 Published February 3, 2023. Accessed February 25, 2023.

Back to Blog